Corcept Therapeutics (CORT) EBITDA Margin (2012 - 2026)

Corcept Therapeutics has disclosed EBITDA Margin across 15 years of filings, most recently posting 30.08% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 30.08%, down 3225.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 1.07% (down 1724.0% YoY), and the FY2025 annual result was 5.88%, down 1440.0% from the prior year.
• EBITDA Margin came in at 30.08% for Q1 2026 at Corcept Therapeutics, down from 2.22% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 31.39% in Q3 2022 to a low of 30.08% in Q1 2026.
• The 5-year median for EBITDA Margin is 21.73% (2024), against an average of 15.81%.
• Across the five-year window, EBITDA Margin soared 604 bps in 2024 and sank 3225 bps in 2026, its largest moves.
• Corcept Therapeutics' EBITDA Margin stood at 21.83% in 2022, then climbed by 7 bps to 23.39% in 2023, then plunged by 41 bps to 13.89% in 2024, then sank by 84 bps to 2.22% in 2025, then plunged by 1455 bps to 30.08% in 2026.
• The last three EBITDA Margin figures came in at 30.08% (Q1 2026), 2.22% (Q4 2025), and 4.92% (Q3 2025), per Business Quant data.